These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1515 related items for PubMed ID: 16938528

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
    Fadare O, Wang SA, Hileeto D.
    Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Mar; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 8. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [Abstract] [Full Text] [Related]

  • 9. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 12. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC, Martyniak A, Kandel MJ, Stadler ZK, Masciari S, Miron A, Richardson AL, Schnitt SJ, Garber JE.
    Am J Surg Pathol; 2009 Jul 01; 33(7):1093-7. PubMed ID: 19390427
    [Abstract] [Full Text] [Related]

  • 13. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ, Cohen C, To TV, Page AJ, Lawson D, Sussman ZM, Nassar A.
    Hum Pathol; 2009 Aug 01; 40(8):1176-81. PubMed ID: 19368951
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.
    Breast Cancer; 2010 Apr 01; 17(2):118-24. PubMed ID: 19466512
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM, Martín A, García C, Corte MD, Alvarez A, Junquera S, González LO, Bongera M, García-Muñiz JL, Allende MT, Vizoso F.
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec 01; 141(2):147-52. PubMed ID: 18768247
    [Abstract] [Full Text] [Related]

  • 17. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ.
    Hum Pathol; 2009 Sep 01; 40(9):1224-33. PubMed ID: 19439346
    [Abstract] [Full Text] [Related]

  • 18. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.
    Hum Pathol; 2008 Dec 01; 39(12):1809-15. PubMed ID: 18715613
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.